Phase I/II Study of Lenalidomide in Combination With Anti-PD-1 Monoclonal Antibody CT-011 in Patients With Relapsed/Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Lenalidomide (Primary) ; Pidilizumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 04 Dec 2017 Planned primary completion date changed from 30 Jun 2017 to 30 Jun 2018.
- 03 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2016 Status changed from suspended to recruiting.